You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

CUBICIN RF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cubicin Rf, and when can generic versions of Cubicin Rf launch?

Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in thirty-one countries.

The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

US ANDA Litigation and Generic Entry Outlook for Cubicin Rf

A generic version of CUBICIN RF was approved as daptomycin by HOSPIRA INC on September 12th, 2014.

  Start Trial

Drug patent expirations by year for CUBICIN RF
Recent Clinical Trials for CUBICIN RF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vancouver Island Health AuthorityPhase 4
Poitiers University HospitalPhase 3
University Hospital Inselspital, BernePhase 1

See all CUBICIN RF clinical trials

Pharmacology for CUBICIN RF
Paragraph IV (Patent) Challenges for CUBICIN RF
Tradename Dosage Ingredient NDA Submissiondate
CUBICIN RF POWDER;INTRAVENOUS daptomycin 021572 2008-11-19
CUBICIN POWDER;INTRAVENOUS daptomycin 021572 2008-11-19

US Patents and Regulatory Information for CUBICIN RF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CUBICIN RF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1115417 SZ 22/2006 Austria   Start Trial PRODUCT NAME: DAPTOMYCIN
1115417 SPC 018/2006 Ireland   Start Trial SPC 018/2006: 20070523, EXPIRES: 20210118
1115417 300232 Netherlands   Start Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN DE JURIDISCHE ENTITEIT
1115417 91254 Luxembourg   Start Trial 91254, EXPIRES: 20210119
1115417 22/2006 Austria   Start Trial PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
1115417 SPC/GB06/024 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
Moodys
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.